百特醫療 (BAX) 2018 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, ladies and gentlemen, and welcome to Baxter International's First Quarter 2018 Earnings Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time. I would now like to turn the call over to Ms. Clare Trachtman, Vice President, Investor Relations at Baxter International. Ms. Trachtman, you may begin.

    各位女士、先生,早安,歡迎參加百特國際(Baxter International)2018 年第一季財報電話會議。(接線員指示)提醒各位,本次電話會議由百特錄音並受著作權保護。未經百特許可,不得錄製或轉播。如有任何異議,請此刻中斷連線。現在我想把電話交給百特國際投資人關係副總裁 Clare Trachtman 女士。Trachtman 女士,請開始。

  • Clare Trachtman - VP of IR

    Clare Trachtman - VP of IR

  • Thank you, Candice. Good morning, and welcome to our First Quarter 2018 Earnings Conference Call. Joining me today are Joe Almeida, Baxter's Chairman and Chief Executive Officer; and Jay Saccaro, Baxter's Chief Financial Officer.

    謝謝你,Candice。各位早安,歡迎參加我們 2018 年第一季財報電話會議。今天與我一同出席的有百特董事長暨執行長 Joe Almeida,以及百特財務長 Jay Saccaro。

  • On the call this morning, we will be discussing Baxter's first quarter 2018 financial results along with our financial outlook for 2018. A supplemental presentation to complement this morning's discussion can be accessed on our website. This presentation, along with related non-GAAP reconciliations, can be accessed on Baxter's external website in the Investors section under Events and Presentations.

    今天上午的電話會議中,我們將討論百特 2018 年第一季財務結果,以及我們對 2018 年的財務展望。可至我們網站取得補充簡報,以配合今天上午的討論。該簡報以及相關的非 GAAP 調節表,可於百特對外網站「投資人」專區的「活動與簡報」中取得。

  • As reminder, Baxter will be hosting an investor conference on May 21 in New York City with presentations beginning at 8 a.m. Eastern Time. At the conference, we will be providing an update on our strategic road map and long-term financial aspirations, along with showcasing our promising new product pipeline at our innovation hall. The innovation hall will be open before and after the presentation. Registration information and additional details can be found in the Investors section of baxter.com on the Events and Presentations page.

    提醒各位,百特將於 5 月 21 日在紐約市舉辦投資人會議,簡報將於美東時間上午 8 點開始。在會議中,我們將更新策略路線圖與長期財務目標,並在創新展示區呈現我們具前景的新產品研發管線。創新展示區將於簡報前後開放。報名資訊與更多細節可於 baxter.com 的「投資人」專區「活動與簡報」頁面查詢。

  • With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook, new product development, business development and regulatory matters contain forward-looking statements that involve risks and uncertainties.

    接下來,在開始我們的準備發言之前,先提醒各位:本簡報(包括關於我們財務展望、新產品開發、業務發展與法規事項的評論)包含前瞻性陳述,並涉及風險與不確定性。

  • And of course, our actual results could differ materially from our current expectations.

    當然,我們的實際結果可能與目前預期有重大差異。

  • Please refer to today's press release and our SEC filings for more details concerning factors that could cause actual results to differ materially.

    請參閱今日新聞稿以及我們向美國證券交易委員會(SEC)提交的文件,以了解可能導致實際結果與預期有重大差異的因素之更多細節。

  • In addition, on today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance.

    此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續性業務表現。

  • A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and available on our website.

    今日所討論之非 GAAP 財務衡量指標與可比較之 GAAP 財務衡量指標的調節表,已包含於我們今早發布並可於網站取得的財報新聞稿中。

  • Now I'd like to turn the call over to Joe.

    現在我想把電話交給 Joe。

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Good morning, everyone, and thank you for joining us today. I will start with a brief look at our first quarter performance. Then I will share a few thoughts about our ongoing transformation in advance of our upcoming investor conference. Jay will then take a closer look at the Q1 financials and provide an update on our guidance for the rest of the year. We will close with Q&A.

    各位早安,感謝今天加入我們。我將先簡要回顧第一季的表現。接著,在即將到來的投資人會議之前,我會分享一些我們持續轉型的想法。之後 Jay 將更深入檢視第一季財務表現,並更新我們對今年其餘期間的財測指引。最後我們將進行問答。

  • Baxter kicked off 2018 with strong results, delivering solid top line performance and maintaining the momentum we have built over the course of our business transformation. Sales in the first quarter increased 8% on a reported basis, 4% on a constant currency basis and 3% operationally.

    百特以強勁的成績揭開 2018 年序幕,繳出穩健的營收表現,並延續我們在業務轉型過程中所建立的動能。第一季銷售額以申報基礎計算成長 8%,以固定匯率基礎計算成長 4%,以營運基礎計算成長 3%。

  • As a reminder, first quarter operational sales adjust for the impact of foreign exchange, generic competition for cyclophosphamide in the U.S. and the Claris acquisition. On the bottom line, adjusted earnings per share were $0.70, increasing 21% year-over-year. This growth reflects the positive contribution of our top line performance, continuous operational efficiency improvements, a benefit from recent changes to our U.S. pension plan and a lower tax rate.

    提醒各位,第一季營運基礎銷售額已調整外匯影響、美國環磷醯胺(cyclophosphamide)面臨學名藥競爭的影響,以及 Claris 併購案的影響。在獲利方面,調整後每股盈餘為 0.70 美元,年增 21%。此成長反映了營收表現的正面貢獻、持續的營運效率改善、近期美國退休金計畫變更帶來的效益,以及較低的稅率。

  • In line with our outlook, first quarter sales were negatively affected by approximately $25 million due to the temporary manufacturing disruption in Puerto Rico related to Hurricane Maria. As we indicated on our Q4 call, these facilities were already ramping up to prehurricane production levels in January. This significant milestone, coupled with the FDA's granting of regulatory discretion for temporary special importation of certain products, have facilitated our return to a minimum of 100% customer allocation for all major product categories connected with our Puerto Rico operations.

    符合我們的展望,第一季銷售額因波多黎各與颶風瑪麗亞相關的暫時性製造中斷而受到約 2,500 萬美元的負面影響。如同我們在第四季電話會議所指出,這些設施在 1 月已開始回升至颶風前的產能水準。這一重要里程碑,加上 FDA 核准對部分產品進行臨時特殊進口的監管裁量,已促成我們恢復對所有與波多黎各營運相關的主要產品類別,至少達到 100% 的客戶配給水準。

  • We'd like to recognize the critical collaboration and support of the FDA in helping us address product supply and relay our continued gratitude to our customers and patients as we worked to resolve this supply challenge. At this point, we do not expect any further revenue impact due to the Hurricane Maria.

    我們要肯定 FDA 在協助我們處理產品供應方面所展現的關鍵合作與支持,並在我們努力解決此供應挑戰的過程中,持續感謝客戶與病患的體諒與支持。就目前而言,我們預期颶風瑪麗亞不會再對營收造成進一步影響。

  • In addition, we continue to identify opportunities to strengthen and optimize our global manufacturing supply network. In the quarter, following a receipt of permanent approval from FDA, we increased shipments of large volume IV solutions from Mexico to the U.S. to address increased U.S. demand. Going forward, we will look to reallocate additional IV solutions volume from select South American manufacturing facilities to the U.S. This action will allow us to complete remediation activities and modernize production processes at certain manufacturing facilities in the U.S. and Puerto Rico.

    此外,我們持續尋找機會,以強化並最佳化全球製造供應網路。本季在取得 FDA 的永久核准後,我們增加自墨西哥運往美國的大容量靜脈輸液(IV solutions)出貨,以因應美國需求上升。展望未來,我們將把部分南美製造據點的更多靜脈輸液產量重新配置至美國。此舉將使我們得以在美國與波多黎各的部分製造設施完成改善(remediation)作業並使生產流程現代化。

  • The reallocation of this volume will help us ensure that we have appropriate supply levels to service both existing and new customers in the U.S. market during the period of remediation and modernization and beyond.

    這些產量的重新配置將有助於我們在改善與現代化期間及其後,確保具備適當的供應水準,以服務美國市場的既有與新客戶。

  • Innovation is essential to our growth equation, and as our Q1 highlights reflect, we're focused on driving growth, both organically and inorganically for optimal impact. Last month, we completed our acquisition of RECOTHROM and PREVELEAK from Mallinckrodt, bringing additional depth to our advanced surgery portfolio of hemostats and sealants. These 2 products are already enhancing our portfolio by offering surgeons additional Baxter options when intraoperative bleeding may occur.

    創新是我們成長方程式中的關鍵,而從第一季重點可見,我們專注於推動成長,並以有機與無機方式並進,以達到最佳效果。上個月,我們完成自 Mallinckrodt 收購 RECOTHROM 與 PREVELEAK,為我們的先進外科止血與封合產品組合增添更深厚的布局。這兩項產品已透過在術中可能發生出血時,為外科醫師提供更多百特選項,進一步強化我們的產品組合。

  • In addition, our advanced surgery team recently began the launch of TISSEEL Prima in Europe. TISSEEL Prima is a significant enhancement of our market-leading TISSEEL fibrin sealant, now offering surgeons greater speed, precision and control during applications through a fully assembled redesigned syringe.

    此外,我們的先進外科團隊近期已在歐洲開始推出 TISSEEL Prima。TISSEEL Prima 是我們市場領先的 TISSEEL 纖維蛋白封合劑的一項重大升級,透過全組裝、重新設計的注射器,讓外科醫師在施用時具備更高的速度、精準度與控制性。

  • Taken together, these developments reflect our broader commitment to driving surgical innovation and the importance we place on advanced surgery as a core growth opportunity.

    綜合而言,這些進展反映我們推動外科創新的更廣泛承諾,以及我們將先進外科視為核心成長機會的重要性。

  • In Japan, our renal care team began the launch of Baxter's KAGUYA peritoneal dialysis technology. KAGUYA is very similar to our AMIA APD system while also incorporating several distinct features, reflecting local needs and patient demographics. Currently, nearly all of Japan's end-stage renal disease patients are treated through in-center hemodialysis. We believe KAGUYA represents an important option to facilitate more patients choosing PD therapy as their preferred treatment choice. Early feedback has been positive.

    在日本,我們的腎臟照護團隊已開始推出百特的 KAGUYA 腹膜透析技術。KAGUYA 與我們的 AMIA 自動腹膜透析(APD)系統非常相似,同時也納入數項獨特功能,以反映當地需求與病患族群特性。目前,日本幾乎所有末期腎臟病患者皆以院內血液透析治療。我們相信 KAGUYA 是一項重要選擇,可促進更多病患將腹膜透析(PD)療法作為其偏好的治療方式。初期回饋相當正面。

  • All-in, our Q1 results and efforts we've made to strengthen both our innovation pipeline and our manufacturing operations reflect the swift, steady progress we have made on Baxter's strategic transformation. We remain focused on our mission to save and sustain lives and on our top quartile performance goals.

    整體而言,我們第一季的結果,以及我們為強化創新研發管線與製造營運所做的努力,反映出我們在百特策略轉型上所取得的快速且穩健的進展。我們仍專注於「拯救並延續生命」的使命,以及躋身同業前四分位的績效目標。

  • At the same time, our objective is to accelerate growth by expanding Baxter's impact across the health care spectrum, supported by the evolution of our new product pipeline. We look forward to sharing more information in just a few short weeks at our upcoming investor conference, where we will outline the next chapter in our strategy and what's in store across our businesses.

    同時,我們的目標是透過擴大百特在整體醫療照護領域的影響力來加速成長,並以新產品研發管線的演進作為支撐。我們期待在幾週後即將舉行的投資人會議上分享更多資訊,屆時我們將概述策略的下一篇章,以及我們各項業務的未來規劃。

  • And now I'll pass it over to Jay, who will walk you through the quarter's financials in more detail.

    現在我把時間交給 Jay,他將更詳細地帶大家了解本季的財務表現。

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Thanks, Joe, and good morning, everyone. As Joe mentioned, we're encouraged by our first quarter results, which represented a strong start to the year. I'll start by discussing our first quarter results before providing our updated financial outlook for 2018.

    謝謝你,Joe,各位早安。如 Joe 所提到的,我們對第一季的結果感到鼓舞,這代表今年有一個強勁的開局。我將先說明第一季的業績,接著提供我們更新後的 2018 年財務展望。

  • Beginning with the first quarter, global sales of $2.7 billion exceeded guidance, increasing 8% on a reported basis, 4% at constant currency and 3% on an operational basis.

    先從第一季開始,全球銷售額為 27 億美元,超出指引;以報告基礎計算成長 8%,以固定匯率計算成長 4%,以營運基礎計算成長 3%。

  • Key growth drivers for the quarter included strong demand for the company's continuous Renal replacement therapies due to an intense flu season, increased sales of injectable pharmaceuticals and advanced surgery products as well as IV solutions and peritoneal dialysis therapies. As previously mentioned, disruptions to our Puerto Rico manufacturing facility negatively impacted first quarter sales by approximately $25 million. And as Joe mentioned, we do not expect any further impact to revenue moving forward.

    本季的主要成長動能包括:因流感季節嚴峻而帶動公司連續性腎臟替代療法(CRRT)的強勁需求、注射劑藥品與先進手術產品銷售增加,以及靜脈輸液(IV)溶液與腹膜透析療法的成長。如先前所述,波多黎各製造廠的營運中斷對第一季銷售造成約 2,500 萬美元的負面影響。且如 Joe 所提到的,我們預期未來不會再對營收造成進一步影響。

  • On the bottom line, adjusted earnings increased 21% to $0.70 per diluted share. This exceeded our previous guidance of $0.60 to $0.62 per share driven largely by operational performance and a lower-than-expected tax rate due to certain discrete items we recognized during the quarter.

    在獲利方面,調整後盈餘成長 21%,至每股稀釋後 0.70 美元。此結果高於我們先前每股 0.60 至 0.62 美元的指引,主要受惠於營運表現,以及因本季認列若干一次性項目而使有效稅率低於預期。

  • Now I'll walk you through performance by our new regions and Global Business Units. Note, for this quarter, constant currency sales growth is equal to operational sales growth for all businesses with the exception of our pharmaceuticals business. For this business, we will provide operational growth adjusting for the impact of generic competition for U.S. cyclophosphamide and the Claris acquisition.

    接下來我將依我們新的區域與全球事業單位(Global Business Units)說明表現。請注意,本季除藥品事業外,所有事業的固定匯率銷售成長等同於營運銷售成長。針對藥品事業,我們將提供營運成長,並調整美國 cyclophosphamide 的學名藥競爭影響以及 Claris 併購案的影響。

  • Starting first with sales growth for our 3 regions. Sales in the Americas advanced 4% on a constant currency basis and 3% operationally. Sales in Europe, Middle East and Africa grew 3% constant currency and 2% operationally. And finally, sales in our Asia Pacific region rose 3% on both a constant currency and operational basis.

    先從三大區域的銷售成長談起。美洲地區銷售以固定匯率計算成長 4%,以營運基礎計算成長 3%。歐洲、中東與非洲地區以固定匯率計算成長 3%,以營運基礎計算成長 2%。最後,亞太地區銷售以固定匯率與營運基礎計算皆成長 3%。

  • Moving on to performance by Global Business Units. Global sales for renal care were $868 million, advancing 4% on a constant currency basis. Performance was driven by solid global growth in both our PD and HD businesses.

    接著看全球事業單位的表現。腎臟照護(renal care)全球銷售額為 8.68 億美元,以固定匯率計算成長 4%。表現主要由我們 PD 與 HD 兩項業務在全球的穩健成長所帶動。

  • Sales in medication delivery were $676 million, flat on a constant currency basis. Performance was driven by continued strength for U.S. large volume IV solutions as we were able to clear a number of back orders in the quarter given the additional volume from Mexico. Growth in the quarter was offset by lower sales internationally and the impact from Hurricane Maria.

    藥物輸送(medication delivery)銷售額為 6.76 億美元,以固定匯率計算持平。表現主要受惠於美國大容量 IV 溶液持續強勁;由於墨西哥提供的額外產能,我們得以在本季清理多筆積壓訂單。然而,本季成長被國際市場較低的銷售以及瑪麗亞颶風的影響所抵銷。

  • Pharmaceutical sales were $496 million, increasing 13% constant currency and 6% operationally. Sales growth in the quarter was driven by strength in our U.S. injectables business, which benefited from increased sales of BREVIBLOC due to competitive supply constraints. Strength in our international hospital pharmacy compounding business also contributed to growth in the quarter. Performance was partially offset by the benefit we recognized last year for Transderm Scop as well as the impact of Hurricane Maria. Sales of U.S. cyclophosphamide were $42 million in the quarter, and Claris contributed $36 million globally.

    藥品(pharmaceuticals)銷售額為 4.96 億美元,以固定匯率計算成長 13%,以營運基礎計算成長 6%。本季銷售成長主要由我們美國注射劑業務的強勁表現帶動,該業務受惠於競爭對手供應受限而使 BREVIBLOC 銷售增加。我們國際醫院藥局調劑(compounding)業務的強勁表現亦對本季成長有所貢獻。不過,去年 Transderm Scop 所帶來的利益,以及瑪麗亞颶風的影響,部分抵銷了本季表現。本季美國 cyclophosphamide 銷售額為 4,200 萬美元,Claris 在全球貢獻 3,600 萬美元。

  • Moving to nutrition. Total sales were $223 million, flat to prior year. Growth in international markets was offset by the impact of Hurricane Maria on U.S. sales. Sales in advanced surgery were $182 million, increasing 4% on a constant currency basis. Performance in this business continues to improve, with sales for our core hemostats and sealants advancing 6% in the quarter. As mentioned previously, we completed the acquisition of RECOTHROM and PREVELEAK late in the quarter. Sales in the quarter were immaterial for these products.

    接著是營養(nutrition)。總銷售額為 2.23 億美元,與去年同期持平。國際市場的成長被瑪麗亞颶風對美國銷售的影響所抵銷。先進手術(advanced surgery)銷售額為 1.82 億美元,以固定匯率計算成長 4%。該業務表現持續改善,我們核心止血劑與封合劑(hemostats and sealants)本季銷售成長 6%。如先前所述,我們在本季末完成 RECOTHROM 與 PREVELEAK 的收購。本季這些產品的銷售貢獻不具重大性。

  • Sales in our acute therapies business were $129 million, representing growth of 14% on a constant currency basis. Contributing to growth in the quarter was strength in global demand for Baxter's CRRT therapies as well as a benefit from an intense flu season, which contributed approximately 7 points of growth in the quarter.

    急性療法(acute therapies)業務銷售額為 1.29 億美元,以固定匯率計算成長 14%。本季成長的貢獻因素包括:全球對 Baxter CRRT 療法的強勁需求,以及嚴峻流感季節帶來的助益;後者約貢獻本季 7 個百分點的成長。

  • Finally, sales in our other category, which primarily includes our contract manufacturing services, declined 12% to $103 million on a constant currency basis. Performance in the quarter was impacted by the timing of certain items compared to the prior year period.

    最後,其他(other)類別(主要包含委外製造服務)以固定匯率計算下滑 12%,至 1.03 億美元。本季表現受到若干項目相較去年同期之認列時點差異所影響。

  • Moving through the rest of the P&L, our adjusted gross margin of 43.8% declined 60 basis points over the prior year. Underlying operational expansion of more than 100 basis points was more than offset by a negative impact from foreign exchange, the impact from lost sales due to Hurricane Maria and incremental supply chain costs we absorbed during the quarter.

    接著看損益表其餘項目,我們調整後毛利率為 43.8%,較去年同期下降 60 個基點。雖然營運面基本擴張超過 100 個基點,但被外匯的負面影響、瑪麗亞颶風造成的銷售流失,以及本季我們吸收的額外供應鏈成本所抵銷。

  • Adjusted SG&A totaled $587 million, increasing 6% on a reported basis and 1% on a constant currency basis. The positive contribution from our relentless focus on effectively managing our expense base was offset by lower transition service agreement income from Shire and increased freight expense as we work to ensure adequate product availability to meet our customer needs. The acquisition of Claris also added 1 point of SG&A growth in the quarter.

    調整後銷售、一般及管理費用(SG&A)合計 5.87 億美元,以報告基礎計算增加 6%,以固定匯率計算增加 1%。我們持續專注於有效管理費用基礎所帶來的正面貢獻,被 Shire 的過渡服務協議(TSA)收入下降,以及為確保充足產品供應以滿足客戶需求而增加的運輸費用所抵銷。Claris 的併購亦使本季 SG&A 成長增加 1 個百分點。

  • Adjusted R&D spending in the quarter of $137 million increased 6% on a reported basis and was flat on a constant currency basis to the prior year period. R&D expenses in the quarter were impacted by the timing of certain project-related spend, which is expected to pick up in the second quarter of 2018.

    本季調整後研發(R&D)支出為 1.37 億美元,以報告基礎計算增加 6%,以固定匯率計算與去年同期持平。本季研發費用受到部分專案相關支出時點的影響,預期將在 2018 年第二季回升。

  • Adjusted operating margin in the quarter was 16.7%, a decline of 10 basis points versus the prior year. Strong operational expansion of approximately 300 basis points in the quarter was more than offset by the loss of transition service income, foreign exchange and the impact of Hurricane Maria on lost sales and increased supply chain expenses.

    本季調整後營業利益率為 16.7%,較去年同期下降 10 個基點。本季約 300 個基點的強勁營運擴張,被過渡服務收入的流失、外匯影響,以及瑪麗亞颶風造成的銷售流失與供應鏈費用增加所抵銷。

  • Net interest expense was $12 million in the first quarter. Adjusted other income totaled $18 million in the quarter, primarily reflecting foreign exchange gains on balance sheet positions and a benefit from the recent changes we made to our U.S. pension plan. These changes to our U.S. pension plan included separating out the current plan into 2 plans for active and nonactive employees as well as announcing a prospective freeze for the active plan effective December 2022. The benefits of these changes is primarily recognized in other income due to the adoption of new accounting guidance, which requires the recognition of service costs for active employees in operating income and all other components of pension expense in other income. Previously, all of pension expense was reported as part of operating expenses. Results for 2017 have been restated to reflect the change.

    第一季淨利息費用為 1,200 萬美元。本季調整後其他收入合計 1,800 萬美元,主要反映資產負債表部位的外匯收益,以及我們近期對美國退休金計畫所做變更帶來的利益。這些對美國退休金計畫的變更包括:將現行計畫拆分為在職與非在職員工兩個計畫,並宣布在職計畫將自 2022 年 12 月起採前瞻性凍結。由於採用新的會計指引,這些變更的利益主要認列於其他收入;該指引要求在職員工的服務成本認列於營業利益,而退休金費用的其他所有組成部分認列於其他收入。先前,退休金費用全數列報於營業費用中。2017 年的結果已重編以反映此變更。

  • The adjusted tax rate was 14.5% for the quarter, which reflected a benefit of $13 million from FAS 123R stock compensation guidance as well as certain discrete items we recognized in the quarter that favorably impacted the rate. And as previously mentioned, adjusted earnings of $0.70 per diluted share exceeded our guidance of $0.60 to $0.62 per share driven by operational performance and a lower tax rate.

    本季調整後有效稅率為 14.5%,其中包含依 FAS 123R 股權薪酬指引帶來的 1,300 萬美元利益,以及本季認列的若干一次性項目,對稅率產生有利影響。且如先前所述,調整後每股稀釋後盈餘 0.70 美元高於我們每股 0.60 至 0.62 美元的指引,主要由營運表現與較低的稅率所帶動。

  • During the first quarter, we repurchased $522 million or 7.7 million shares. These repurchases were somewhat offset by option-related dilution in the quarter.

    在第一季,我們回購了5.22億美元或770萬股。這些回購在本季部分被與選擇權相關的稀釋所抵銷。

  • Before turning to our 2018 outlook, I will provide some commentary regarding our cash flow performance.

    在談到我們對2018年的展望之前,我將就我們的現金流表現提供一些評論。

  • In the first quarter, we generated free cash flow of $292 million, an improvement of approximately $210 million versus the prior year. Growth was driven by underlying operational performance along with continued focus on improving the company's working capital performance, most notably in our days payable. In addition, cash flows during the quarter benefited from a $70 million payment for the settlement of certain claims related to the acquired operations of Claris.

    在第一季,我們產生了2.92億美元的自由現金流,較去年同期改善約2.10億美元。成長主要由基本營運表現所帶動,同時我們持續聚焦改善公司的營運資金表現,尤其是在應付帳款天數方面。此外,本季現金流亦受惠於一筆7,000萬美元的款項,該款項係用於和解與所收購之Claris營運相關的若干索賠。

  • Let me conclude my comments this morning by providing our guidance for the second quarter and full year 2018. Globally, we now expect 2018 full year sales to increase between 7% to 8% on a reported basis, approximately 5% on a constant currency basis and between 4% and 5% on an operational basis. Operational growth excludes the impact of foreign exchange, sales of U.S. cyclophosphamide, sales from the first 7 months of Claris and sales of RECOTHROM and PREVELEAK.

    最後,讓我在今天上午的發言以提供我們對第二季及2018全年之指引作結。在全球範圍內,我們目前預期2018全年銷售額以報告基礎計將成長7%至8%,以固定匯率基礎計約成長5%,以營運基礎計成長4%至5%。營運成長不包含外匯影響、美國環磷醯胺(cyclophosphamide)銷售、Claris前7個月的銷售,以及RECOTHROM與PREVELEAK的銷售。

  • Moving to guidance by business on a constant currency basis and operational basis, except where otherwise noted. In renal care, we continue to expect growth of 3% to 4%. In medication delivery, we now expect sales to increase 7% to 8%. We now expect our pharmaceuticals business to increase 1% to 2% constant currency. This assumes 2018 U.S. cyclophosphamide sales of $120 million versus previous guidance of $95 million.

    接著按業務別說明指引,除非另有註明,均以固定匯率基礎與營運基礎呈現。在腎臟照護方面,我們仍預期成長3%至4%。在給藥(medication delivery)方面,我們目前預期銷售額將成長7%至8%。我們目前預期製藥業務以固定匯率計將成長1%至2%。此假設2018年美國環磷醯胺銷售為1.20億美元,高於先前指引的9,500萬美元。

  • We expect sales of Claris to contribute approximately $145 million. Excluding the impact of these sales, operational growth is expected to increase approximately 1%.

    我們預期Claris的銷售將貢獻約1.45億美元。排除這些銷售的影響後,預期營運成長約增加1%。

  • Moving to nutrition. We continue to expect sales growth of 4% to 5%. For our advanced surgery business, we expect sales to increase 8% to 9% on a constant currency basis. This includes a contribution of approximately $40 million related to the recent acquisition of RECOTHROM and PREVELEAK. Excluding the impact of these sales, operational growth is expected to be 3% to 4%.

    接著談營養(nutrition)。我們仍預期銷售成長4%至5%。在先進外科(advanced surgery)業務方面,我們預期以固定匯率計銷售將成長8%至9%。其中包含近期收購RECOTHROM與PREVELEAK所帶來約4,000萬美元的貢獻。排除這些銷售的影響後,預期營運成長為3%至4%。

  • For the acute therapies business, we now anticipate growth of 9% to 10% given the strong first quarter performance. Finally, in our other business, we continue to expect low single-digit declines in sales.

    在急性療法(acute therapies)業務方面,鑑於第一季表現強勁,我們目前預期成長9%至10%。最後,在其他業務方面,我們仍預期銷售將出現低個位數的下滑。

  • Moving down the P&L. We continue to anticipate adjusted operating margin expansion of 80 to 100 basis points. We expect net interest expense of approximately $55 million, and adjusted other income between $55 million and $75 million for 2018.

    接著往下看損益表。我們仍預期調整後營業利益率將擴張80至100個基點。我們預期2018年淨利息費用約為5,500萬美元,調整後其他收入介於5,500萬至7,500萬美元。

  • For the year, we now expect an average adjusted tax rate of approximately 19%. The tax rate reflects the lower rate we recorded during the first quarter.

    就全年而言,我們目前預期平均調整後稅率約為19%。該稅率反映了我們在第一季認列的較低稅率。

  • For full year 2018, we anticipate a diluted average share count of approximately 550 million shares. This reflects the benefit of ongoing share repurchases. Based on these factors, we expect 2018 adjusted earnings, excluding special items, of $2.85 to $2.93 per diluted share.

    就2018全年而言,我們預期稀釋後平均股數約為5.50億股。這反映了持續回購股份所帶來的效益。基於上述因素,我們預期2018年調整後盈餘(不含特殊項目)為每股稀釋後2.85至2.93美元。

  • Finally, for the year, we now expect to generate operating cash flow of more than $2.2 billion, capital expenditures of approximately $700 million and free cash flow of more than $1.5 billion.

    最後,就全年而言,我們目前預期營運現金流將超過22億美元,資本支出約為7.00億美元,自由現金流將超過15億美元。

  • Specific to the second quarter of 2018, we expect sales growth of approximately 9% on a reported basis and 5% on a constant currency basis. Operationally, sales in the second quarter are expected to increase 3% to 4%, and we expect adjusted earnings, excluding special items, of $0.69 to $0.71 per diluted share.

    針對2018年第二季,我們預期以報告基礎計銷售成長約9%,以固定匯率基礎計成長5%。以營運角度來看,第二季銷售預期成長3%至4%,且我們預期調整後盈餘(不含特殊項目)為每股稀釋後0.69至0.71美元。

  • With that, we can open up the call for Q&A.

    接下來,我們可以開放問答。

  • Operator

    Operator

  • (Operator Instructions) And our first question comes from David Lewis of Morgan Stanley.

    (接線員指示) 我們的第一個問題來自摩根士丹利(Morgan Stanley)的David Lewis。

  • Unidentified Analyst

    Unidentified Analyst

  • This is [Varun] on for David. I just had a quick question on second quarter guidance. Just kind of walking through, so you did 3% in the first quarter, and your guidance is maybe 3% to 4% operational ex cyclo for the second quarter. Just given the easier comp, and maybe the hurricane gives you 1 point and you've got Transderm as well, maybe that's another point. Just wanted to understand if there's maybe something that we're missing that kind of leaves the growth for next quarter at only 3% to 4%.

    我是[Varun],代替David提問。我有一個關於第二季指引的簡短問題。簡單梳理一下,你們第一季做了3%,而你們對第二季的指引是營運面(不含cyclo)約3%到4%。考量到比較基期較容易,且颶風可能帶來1個百分點,再加上Transderm可能也是1個百分點。我想了解是否有我們遺漏的因素,導致下季成長仍只有3%到4%。

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • No, certainly, look, as we look at the growth rate moving into the balance of the year, it's largely consistent with what we've said in the past. For us, as we look at the second quarter, there was about 1 point of impact related to the hurricane that we saw in the first quarter. So you could adjust for that, see a growth rate more along the lines of 4%. And like -- as we said, the balance of the new products impact in -- as we look at 2018 will come in the second half of the year. So one of the reasons why we've been able to guide to 4% previously and now 4% to 5% relates to the benefits of the new products that we'll be launching this year. But a lot of that impact, as I say, comes in the second half of the year through things like KAGUYA along with the version 9 of the SPECTRUM pump. So really, that's what drives the acceleration in the back half of the year relative to Q2.

    不,當然沒有。你看,當我們觀察進入今年剩餘期間的成長率時,基本上與我們過去所說的一致。就我們而言,第二季大約有1個百分點的影響與我們在第一季看到的颶風相關。因此你可以就此調整,看到更接近4%的成長率。而且如同我們所說,2018年新產品影響的其餘部分將在下半年顯現。因此,我們先前能指引到4%,而現在能指引到4%到5%,其中一個原因就是今年將推出的新產品所帶來的效益。但如我所說,其中很大一部分影響會在下半年出現,透過像KAGUYA以及SPECTRUM幫浦第9版等產品。所以,真正推動下半年相較於第二季加速的,就是這些因素。

  • Operator

    Operator

  • And our next question comes from Vijay Kumar of Evercore.

    下一個問題來自Evercore的Vijay Kumar。

  • Vijay Muniyappa Kumar - MD & Fundamental Research Analyst

    Vijay Muniyappa Kumar - MD & Fundamental Research Analyst

  • So Jay, maybe one starting on the guidance. I just want to understand if the organic core was raised by 100 basis points because we had the Mallinckrodt deal close. When I look at your acquisition contribution, it really didn't change. So I'm just trying to understand what's the core operational increase for the year.

    Jay,先從指引開始。我想了解,是否因為Mallinckrodt交易完成,使得有機核心成長上調了100個基點。但我看你們的併購貢獻其實沒有變。所以我想弄清楚,今年核心營運成長的上調幅度到底是多少。

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Yes. Just to give you little background on the core operational growth of 4% to 5%, there are 3 items that, that excludes. First, it excludes 70 basis points of Claris. So basically, 7 months of Claris sales are excluded from the operational sales growth. The second item that it excludes is the cyclo impact, which, on a year-over-year basis, we now expect to be around 70 basis points. And finally, the Mallinckrodt acquisition is also excluded from operational growth. And that's about 40 basis points of impact. So that's the drivers of the difference between constant currency growth and operational growth. Really, the primary reason why we've raised operational growth from the 4% to 5% was the solid Q1 performance that -- and we expect that to kind of hold throughout the rest of the year. That was really the driver that led to the increase.

    是的。就4%到5%的核心營運成長,先提供一些背景:其中排除了三個項目。第一,排除了Claris的70個基點。也就是說,Claris的7個月銷售被排除在營運銷售成長之外。第二個排除項目是cyclo的影響;以年對年來看,我們目前預期約為70個基點。最後,Mallinckrodt的收購也被排除在營運成長之外。其影響約為40個基點。以上就是固定匯率成長與營運成長之間差異的驅動因素。我們之所以上調營運成長至4%到5%,主要原因是第一季表現穩健,而且我們預期這種表現將在今年剩餘期間大致延續。這才是促成上調的真正驅動因素。

  • Vijay Muniyappa Kumar - MD & Fundamental Research Analyst

    Vijay Muniyappa Kumar - MD & Fundamental Research Analyst

  • That's helpful, Jay. And then one on margins, maybe. I think you mentioned FX and hurricane in Q1. When we think about that back half, right, again I think if I recall the comments you made on the prior call, pension was supposed to be a headwind. And given now it looks like cyclo is coming in better, pension was actually positive in the Q. I'm just curious on the EPS guidance and margin assumptions given the Q1 strength we've seen.

    這很有幫助,Jay。接著可能再問一題關於利潤率。我想你提到第一季有匯率和颶風的影響。當我們看下半年時,對吧,再次我想如果我沒記錯你在上一通電話會議的評論,退休金原本應該是逆風。但鑑於現在看起來 cyclo 的表現更好,退休金在本季其實是正面貢獻。我只是好奇,在我們看到第一季強勁表現之後,你們對 EPS 指引與利潤率假設是怎麼看的。

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Yes. We did see a little bit of overperformance relative to our Q1 margins. So definitely pleased with that performance. I would tell you that pension is in line with our expectations. And really, because of the accounting change in relation to how we think about the different components of pension, most of the benefit that we're seeing year-over-year takes place in other income or below the operating margin line. It's our expectation that Q1 will roughly be the lowest margin of the year. The 16.7%, that will be lower than what we'll expect to see in the balance of the year. We have a lot of -- a number of good elements coming through in the back 3 quarters, in particular no hurricane impact. Furthermore, we'll start to see impact of some new product launches as I mentioned earlier. But the big headwind that we have relates to cyclophosphamide in the latter part of the year because we are still anticipating a decline in that, which will impact margins a little bit. Having said that, like I say, we do expect a bit of a step-up from Q1 levels to the balance of the year.

    是的。我們確實看到相較於我們第一季利潤率預期有些許超出表現。所以我們對這個表現當然很滿意。我會告訴你,退休金符合我們的預期。而且實際上,由於在我們看待退休金不同組成項目的方式上有會計變更,我們看到的多數年對年效益會反映在其他收入或是在營業利潤率線以下。我們預期第一季大致會是全年最低的利潤率。16.7% 會低於我們預期在今年其餘期間看到的水準。在接下來三個季度,我們有很多——有不少正面因素會逐步顯現,特別是沒有颶風影響。此外,我們也會開始看到一些新產品上市的影響,如我先前提到的。但我們在今年後段最大的逆風與 cyclophosphamide 有關,因為我們仍預期它會下滑,這會對利潤率造成一些影響。話雖如此,如我所說,我們確實預期利潤率會從第一季水準往上提升,並在今年其餘期間維持較高水準。

  • Vijay Muniyappa Kumar - MD & Fundamental Research Analyst

    Vijay Muniyappa Kumar - MD & Fundamental Research Analyst

  • And if maybe I could squeeze one in for Joe. Joe, just on capital deployment, any thoughts and updated thoughts on how you guys are thinking about the capital deployment front?

    如果我可以再塞一題給 Joe。Joe,就資本配置而言,你們對資本部署方面的想法有沒有什麼更新?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Vijay, it hasn't changed. We are very focused on 3 things. We continue to look to deploy capital in dividends; share buybacks, I think we've been very outspoken about that; and M&A. If we don't find the right M&As and we accumulate cash in our balance sheet, we'll buy share back. And our plan is always to continue to increase our dividend year-over-year. So our capital plan's pretty set and unchanged from that point of view.

    Vijay,沒有改變。我們非常專注在三件事上。我們持續把資本用在股利;庫藏股回購,我想我們在這方面一直講得很清楚;以及併購。如果我們找不到合適的併購標的,而資產負債表上的現金累積起來,我們就會回購股票。而我們的計畫一向是持續逐年提高股利。所以我們的資本計畫相當明確,從這個角度來看也沒有改變。

  • Operator

    Operator

  • And our next question comes from Robbie Marcus of JPMorgan.

    下一題來自摩根大通(JPMorgan)的 Robbie Marcus。

  • Robert Justin Marcus - Analyst

    Robert Justin Marcus - Analyst

  • Great. Jay, maybe I could start. You raised EPS guidance well above what you beat in the first quarter. Maybe you could give us a different breakdown of the different buckets of where it's coming from over the balance of the year.

    很好。Jay,我先開始問。你們把 EPS 指引上調到遠高於第一季超預期的幅度。也許你可以用不同的方式拆解一下,說明今年剩餘期間這些增量分別來自哪些項目。

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Great. Robbie, congratulations on your new assignment there. Overall, the EPS guidance was raised -- the midpoint was raised roughly $0.13. Of that, $0.09 of it relates to Q1 overperformance. And from our expectation, the $0.09 breaks down roughly $0.06 of operational performance, and there are a number of components of that where we saw strength and then about $0.03 of financial. And that includes positive things like the tax rate, share count, a number of other items included in that. So that's really the Q1 overperformance. Looking to the balance of the year, the 2 primary changes that we made to the guidance relate to cyclophosphamide. We've added roughly $25 million of cyclo, which is around $0.03. And then we also have adjusted our bottom line to reflect the contribution of Mallinckrodt, which we expect to be approximately $0.01 positive. So on balance, it's roughly a $0.13 raise. We've seen $0.09. We've got another $0.04 to go.

    很好。Robbie,恭喜你有了新的職務任務。整體而言,EPS 指引上調——中位數大約上調了 0.13 美元。其中 0.09 美元與第一季超出表現有關。依我們的看法,這 0.09 美元大致可拆為 0.06 美元來自營運表現,而其中包含多個我們看到走強的組成項目;另外約 0.03 美元來自財務面。這包括像是稅率、股數,以及其他一些項目的正面影響。所以這就是第一季的超出表現。再看今年其餘期間,我們對指引做的兩個主要調整與 cyclophosphamide 有關。我們把 cyclo 增加了約 2,500 萬美元,約等於 0.03 美元。另外我們也調整了最終獲利,以反映 Mallinckrodt 的貢獻,我們預期約為正向 0.01 美元。因此合計大約就是上調 0.13 美元。我們已經看到 0.09 美元。還有另外 0.04 美元要在後續達成。

  • Robert Justin Marcus - Analyst

    Robert Justin Marcus - Analyst

  • Great. And maybe just a follow-up. The 2 businesses that stand out most to me in the quarter are renal care and pharmaceuticals. These are businesses that are experiencing different growth rates than we've seen in the past. So maybe you could just give us some pointers of what happened in the quarter and how sustainable this is going forward.

    很好。再追問一下。本季最讓我注意的兩個業務是腎臟照護與製藥。這兩個業務目前的成長率與我們過去看到的不同。所以也許你可以給我們一些指引,說明本季發生了什麼,以及未來這樣的表現有多可持續。

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Robbie, let's start with renal care. I think our -- the change from last year to this year, which we feel confident is propelling momentum. We have a new agreement with DaVita in the U.S. that has been positive for the company. I think we're -- with DaVita, undertaking this large and vast market of potential PD patients. And I think for the benefit for the patient, both companies are engaged in advancing that modality. And I think with the lawsuit and the issues behind us, I think what we're seeing now is the true growth of the market and the potential that we can achieve together. The second one is the pharmaceutical business. I think what you see there is a lack of competition for cyclophosphamide. That's one thing. I think if you look at the performance of Claris, it has come slightly better than we thought. And we continue to plan to launch the molecules that we had planned in the past. So another item that we would like to comment is BREVIBLOC. BREVIBLOC is a drug that now has competition in the marketplace. However, we secured a customer base that continues to provide us with the business, and this has to do with a competitor who should be in the market and was not, coming later on the year. And we think if they don't come, we'll let you know. If they continue to have problems, BREVIBLOC will continue to grow. If they come as we planned, which is in the guidance actually, we will also experience that competition. So the pharmaceutical business is strong despite the fact that BREVIBLOC has a competitor, and it will continue to do well.

    Robbie,我們先從腎臟照護開始。我認為我們——從去年到今年的變化,我們有信心正在推動動能。我們在美國與 DaVita 簽了新的協議,對公司是正面的。我想我們——與 DaVita 一起,正在開拓一個龐大且廣泛的潛在腹膜透析(PD)病患市場。而且我認為,為了病患的利益,兩家公司都在推動這種治療模式的發展。隨著訴訟與相關問題已經過去,我想我們現在看到的是市場真正的成長,以及我們能共同達成的潛力。第二個是製藥業務。我想你在那裡看到的是 cyclophosphamide 缺乏競爭。這是一點。另外,如果你看 Claris 的表現,它略微比我們原先想的更好。而我們也持續按計畫推出過去規劃的那些分子(產品)。所以我們還想評論的另一項是 BREVIBLOC。BREVIBLOC 這個藥目前在市場上已有競爭者。不過,我們鞏固了一個客戶基礎,仍持續把業務帶給我們;這與某個原本應該在市場上的競爭者沒有如期進入、而是延後到今年稍晚有關。我們認為如果他們沒有進來,我們會告訴各位。如果他們持續有問題,BREVIBLOC 將會持續成長。如果他們如我們規劃般進入——其實這已經反映在指引中——我們也會面臨那樣的競爭。因此,儘管 BREVIBLOC 有競爭者,製藥業務仍然強勁,並且會持續表現良好。

  • Robert Justin Marcus - Analyst

    Robert Justin Marcus - Analyst

  • And do you mind just clarifying what your time lines and guidance are for cyclo competition and for BREVIBLOC?

    你介意再釐清一下你們對 cyclo 競爭進入的時間表與指引假設,以及對 BREVIBLOC 的時間表與指引假設嗎?

  • Clare Trachtman - VP of IR

    Clare Trachtman - VP of IR

  • Sure, Robbie. It's Clare. With respect to BREVIBLOC, we do expect incremental competition starting in this quarter, in the second quarter. For cyclophosphamide, we're assuming the similar run rate in Q2 as we had in Q1, with competition entering in the second half of the year.

    當然,Robbie。我是 Clare。就 BREVIBLOC 而言,我們確實預期從本季、也就是第二季開始會有新增的競爭。至於 cyclophosphamide,我們假設第二季的運行水準(run rate)與第一季相近,而競爭會在下半年進入。

  • Operator

    Operator

  • And our next question comes from Isaac Ro of Goldman Sachs.

    下一題來自高盛(Goldman Sachs)的 Isaac Ro。

  • Isaac Ro - VP

    Isaac Ro - VP

  • Could you give us a little bit of detail on your expectations for gross margin progression for the rest of the year? Appreciate the comments on what went on this quarter. Kind of curious as those roll off, how the impact of new products can kind of help serve as a gross margin tailwind. And just net of those 2 factors, what you guys expect as we exit the year on the gross margin level?

    你們能否更詳細說明一下,對今年剩餘期間毛利率走勢的預期?也謝謝你們對本季情況的評論。我有點好奇,當那些因素逐步消退後,新產品的影響如何能成為毛利率的順風。以及在扣除這兩個因素的淨影響後,你們預期在年底時毛利率水準會落在什麼位置?

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Yes. Overall, we've seen strong performance from our manufacturing team over the course of the last several quarters, all of last year as well. And that has paid off, in part, in our ability to raise gross margin guidance. In the quarter, we did have some negative FX impact. We also had the impact of certain supply chain expenses. As we look to alleviate and address some of the tight supply situation we were seeing across a number of our product lines, in part related to the hurricane, in part related to the intense flu season where there was a lot of incremental freight that we experienced that impacted our gross margin. So looking at gross margin, I would say that Q1 should be the lowest quarter of the year despite the fact that we will see cyclo erosion in the back half of the year. So we had a 43.8, roughly, number. We do expect that to go up in Q2 and Q3, and then -- which will be the highest levels of the year. And then it will be down a little bit relative to Q2, Q3 levels in the fourth quarter. As I said, as the most intense period of cyclo competition emerges. So on balance, like I say, we'll expect roughly flat to last year, recognizing that Q1 is below the full year level from last year.

    是的。整體而言,過去幾個季度、以及去年全年,我們看到製造團隊表現強勁。這也在一定程度上反映在我們能夠上調毛利率指引上。本季度我們確實受到一些不利的外匯影響。我們也承擔了某些供應鏈費用的影響。當我們著手緩解並處理多條產品線所面臨的供應緊張情況時——部分與颶風有關,部分與流感季特別嚴重有關——我們經歷了大量額外的貨運(加急運輸),進而影響了毛利率。因此就毛利率而言,我會說第一季應該會是全年最低的季度,儘管我們會在下半年看到 cyclo 的侵蝕。所以我們大約是 43.8 左右。我們預期第二季與第三季會上升,並且——那將是全年最高水準。接著第四季會相較於第二、第三季的水準略為下降。如我所說,因為 cyclo 競爭最激烈的時期將會出現。因此整體來看,如我所說,我們預期大致與去年持平,同時也要認知到第一季低於去年全年的水準。

  • Isaac Ro - VP

    Isaac Ro - VP

  • Okay, that's helpful. And maybe as a follow-up, are there any implications to the cadence of tax rate for the rest of the year based on those moving parts? Just curious if the quarter-to-quarter tax rate could see some volatility as well.

    好的,這很有幫助。另外追問一下,基於這些變動因素,對今年剩餘期間的稅率節奏是否有任何影響?只是好奇季度之間的有效稅率是否也可能出現一些波動。

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Certainly. The tax rate, we were pleased with a number of items. Obviously, on the FAS 123R it's just an element that happens each quarter, but there were a couple of settlements that impacted our tax rate in the first quarter of the year. We are not expecting or banking on those kinds of settlements moving forward. So we do expect the full year rate to be in line with what I mentioned on the call, better than the original guidance, but in line with what I mentioned earlier in my statements. And the result of that is there is a fairly significant step-up from Q2 to Q4 related to tax. So we'll expect to see that in line with our expectations. And like I say, we're not banking on significant items to occur in the balance of the year.

    當然。稅率方面,我們對若干項目感到滿意。顯然,FAS 123R 只是每季都會發生的一個要素,但在今年第一季有幾項和解事項影響了我們的稅率。我們不預期、也不會把未來建立在這類和解事項之上。因此我們確實預期全年稅率會與我在電話會議中提到的水準一致,優於原先指引,但與我先前發言中提到的內容一致。其結果是,與稅務相關,從第二季到第四季會有相當顯著的上升。所以我們預期會如同我們的預期那樣呈現。而且如我所說,我們不會指望在今年剩餘期間出現重大的特殊項目。

  • Operator

    Operator

  • And our next question comes from Danielle Antalffy of Leerink Partners.

    下一個問題來自 Leerink Partners 的 Danielle Antalffy。

  • Danielle Joy Antalffy - MD, Medical Supplies and Devices

    Danielle Joy Antalffy - MD, Medical Supplies and Devices

  • Jay or Joe, just wanted to -- not trying to front run the analyst meeting, so just want to focus on the back half of the year. And you mentioned operational sales growth acceleration from a slew of new products. Wondering if you could give us a little bit more color, remind us what some of those products are and what businesses and how meaningful they could impact sales growth reacceleration in said businesses.

    Jay 或 Joe,我只是想——不是想搶先分析師會議,所以只想聚焦在今年下半年。你們提到一系列新產品將帶動營運銷售成長加速。想請你們多補充一些細節,提醒我們其中一些產品是什麼、分別屬於哪些業務,以及它們對相關業務的銷售成長再加速可能有多大的影響。

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Yes, certainly. And Danielle, it's important to point out that while new products will play an important role in the back half of the year, we also do benefit from an easy comp in the fourth quarter, in particular, related to hurricane. So I think that's one element to point out. But looking at -- we're very excited about the innovation pipeline. We'll be sharing a lot of detail with all of you at our Investor Day on May 21. Related to the back half of the year, I think really, the 2 most prominent launches and the 2 most important as we think about our long-term expectations for the company relate to the version 9 of the SIGMA SPECTRUM pump. This has an important innovation with respect to auto program and 2-way wireless connectivity. So we think it's an important new feature that we added to the pump, and it's one that we are quite excited about. So that should drive some solid infusion systems growth in the back half of the year. The second piece relates to KAGUYA. This is our cycler in Japan. And for us, this is a great step forward from a technology standpoint for Japan and includes our SHARESOURCE technology. And we look forward to continued -- or growth in that market for the foreseeable future. And that becomes an important long-term item for us. I would say those are the 2 most prominent. But beyond that, there are a number of smaller launches along with geographic expansion that also feature in the second half numbers.

    是的,當然。Danielle,需要指出的是,雖然新產品在下半年會扮演重要角色,但我們也會受惠於第四季相對容易的比較基期,特別是與颶風相關。所以我認為這是一個需要先點出的因素。不過就——我們對創新產品管線感到非常興奮。我們會在 5 月 21 日的投資人日與各位分享很多細節。就下半年而言,我認為最突出的兩項上市、也是我們在思考公司長期展望時最重要的兩項,與 SIGMA SPECTRUM 幫浦第 9 版有關。它在自動程式(auto program)以及雙向無線連線方面有重要創新。因此我們認為這是我們為該幫浦新增的一項重要新功能,我們也對此相當期待。因此這應能在下半年帶動輸注系統的穩健成長。第二項與 KAGUYA 有關。這是我們在日本的 cycler。對我們而言,從日本的技術角度來看,這是很大的進展,並包含我們的 SHARESOURCE 技術。我們也期待在可預見的未來,該市場能持續——或實現成長。而這也會成為我們一項重要的長期項目。我會說這兩項是最突出的。但除此之外,還有許多較小的上市案以及地理擴張,也會反映在下半年的數字中。

  • Danielle Joy Antalffy - MD, Medical Supplies and Devices

    Danielle Joy Antalffy - MD, Medical Supplies and Devices

  • Okay, that's helpful, and one follow-up on the gross margin line of questioning. We're hearing a lot of this earnings season, rising commodity prices and could this be peak margins. I mean, obviously, you guys have a lot of (inaudible) to turn elsewhere outside of the supply chain, but how are you guys thinking about the rising commodity prices and impact to gross margin? And where do you see offsets to that?

    好的,這很有幫助;另外針對毛利率這條問題再追問一下。我們在這個財報季聽到很多關於大宗商品價格上漲、以及毛利率是否已達高峰的討論。我的意思是,顯然你們在供應鏈之外還有很多(聽不清)可以去調整,但你們如何看待大宗商品價格上漲對毛利率的影響?你們認為可以從哪些方面抵銷?

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Certainly. Overall, gross margins for the quarter were largely in line with our expectations. We -- all of the impacts -- again, we did not see a significant variance from what we expected. The biggest item that was a negative related to this freight. But that was not actually freight pricing, rather volumes of expedited freight related to addressing customer shipments. Certainly, this is a real area of focus for us. But our supply chain team, our purchasing team along with our manufacturing team are incredibly focused on offsetting whatever impacts we see in raw material prices like resin or oil with hard savings dollars in other areas to keep us at or better than our budgeted expectations. Part of the reason why we did so well in Q1 along with things moving forward relates to strong performance from our manufacturing supply chain team. We expect that to continue, and we expect to work to offset these cost changes for input material to continue.

    當然。整體而言,本季度毛利率大致符合我們的預期。我們——所有的影響——再次強調,我們並未看到與預期相比有顯著差異。最大的負面項目與這些運輸(freight)有關。但那其實不是運價上漲,而是為了滿足客戶出貨而增加的加急運輸量。當然,這是我們真正聚焦的一個領域。不過,我們的供應鏈團隊、採購團隊以及製造團隊都非常專注於:用其他領域的硬性節省金額,去抵銷我們在樹脂或油等原物料價格上看到的任何影響,讓我們能維持在、或優於預算預期。我們在第一季表現良好、以及未來推進的一部分原因,與我們製造供應鏈團隊的強勁表現有關。我們預期這會持續,並且我們也預期會持續努力抵銷投入材料成本的這些變動。

  • Operator

    Operator

  • And our next question comes from Joanne Wuensch of BMO Capital Markets.

    下一個問題來自 BMO Capital Markets 的 Joanne Wuensch。

  • Matthew Donald Henriksson - Associate

    Matthew Donald Henriksson - Associate

  • This is Matt Henriksson in for Joanne. My first question is on a little more color on KAGUYA. How do you guys see the PD market opportunity in Japan? And is there any numbers that you guys could provide?

    我是 Matt Henriksson,代替 Joanne 提問。我的第一個問題是想請你們對 KAGUYA 再多補充一些細節。你們如何看待日本 PD 市場的機會?以及你們是否能提供任何數字?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • We feel that the market is very underpenetrated. Today, there's only 3% of the population eligible for dialysis. That is in peritoneal dialysis. And one of the biggest impediments was the fear of peritonitis and contamination. What KAGUYA does, it has automatic assembly of the connecting tubes in the catheter. So it's hands-free. This device, we just got reports that we are really doing extremely well in our prelaunch efforts in Japan. It looks like it's taking off. So the market in Japan is highly profitable market but was always underpenetrated. So with this launch, we hope that we can unlock the market by providing technology that puts at ease the fear of contamination and peritonitis. So it's a milestone launch for Baxter.

    我們認為這個市場的滲透率非常低。目前,符合透析資格的人口中,只有 3%是在做腹膜透析(peritoneal dialysis)。而最大的阻礙之一是對腹膜炎與污染的恐懼。KAGUYA 的作用在於,它能自動組裝導管中的連接管路。因此可以免手操作。我們剛收到報告,顯示我們在日本的上市前推廣工作表現非常、非常好。看起來正在快速起量。因此,日本市場是高獲利市場,但一直以來滲透率偏低。透過這次上市,我們希望能藉由提供能減輕對污染與腹膜炎恐懼的技術,來解鎖這個市場。因此,這對 Baxter 而言是一個里程碑式的上市。

  • Matthew Donald Henriksson - Associate

    Matthew Donald Henriksson - Associate

  • No, that's very helpful. And then my follow-up question is kind of going back to capital allocation. You guys have talked about acquisitions being an important factor for revenue growth going forward into 2020 and beyond. But you also don't like to have the large transformational acquisitions. Is there any commentary that you guys can give us on the Goldilocks kind of size of an acquisition that gives you that revenue growth without being too large?

    不,這非常有幫助。接著我的追問有點回到資本配置。你們談到收購將是推動營收成長、延伸到2020年及之後的重要因素。但你們也不喜歡做大型、具轉型性的收購。你們能否評論一下所謂「剛剛好」(Goldilocks)規模的收購:既能帶來營收成長、又不至於太大?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • I like the term Goldilocks. I was thinking about -- I kind of pictured that right away instead of the acquisitions we have in mind. We don't put the size as much as what are the adjacencies to our business that lend themselves for acquisitions, okay? We are not pursuing white space acquisitions, meaning, large acquisitions that have very little synergistic value to the company. But we are pursuing acquisitions, anything from $50 million to $3 billion, $4 billion, okay? So those are -- that's the space that we can play. We have the balance sheet to do so. But as I say all the time, it's all about the return, the returns, our ability to integrate successfully, preserve the culture, all the good things that I think we have done with Claris, for instance. Mallinckrodt was a small acquisition, but the integration is similar, has gone extremely well. So we are pursuing very hard, acquisitions. It's not -- we have a very good team in place. So the sizes are not what guides us, but the opportunity to really create value for our shareholders. As I said, double-digit internal rate of return, 500, 600 basis points better than our cost of capital, including debt, cost of debt. I'd say about having an ROIC the 3 to 5 years [gets] the company average. And we've been doing a good job with returning invested capital, return on assets, company has done a good job in creating momentum on those 2 indexes. And more so, create long-term growth that has -- that is a market that is equal or better to what Baxter currently competes in. So I would say that, stay tuned. If we don't find those acquisitions, for whatever reason, they don't pan out, we have the balance sheet at our disposal to continue to buy, aggressively, shares back.

    我喜歡「Goldilocks」這個詞。我剛剛在想——我腦中立刻浮現的是那個畫面,而不是我們心中想做的收購。我們不太以規模為出發點,而是看哪些與我們業務相鄰的領域適合透過收購來擴展,好嗎?我們不追求所謂的「白地」收購,也就是與公司協同效益很低的大型收購。但我們確實在尋求收購,規模大概從5,000萬美元到30億、40億美元都可以,好嗎?所以——那是我們可以操作的範圍。我們的資產負債表有能力做到。但我一直說,關鍵在於報酬、報酬率,我們能否成功整合、保留文化,以及所有我認為我們在例如Claris上做得很好的事情。Mallinckrodt是一筆小型收購,但整合方式類似,而且進展非常順利。所以我們正非常積極地推動收購。這不是——我們有一支非常好的團隊。因此,引導我們的不是規模,而是能否真正為股東創造價值的機會。如我所說,內部報酬率要達到兩位數,比我們的資本成本高出500到600個基點,包含負債、債務成本。我會說,ROIC在3到5年內要達到公司平均水準。而我們在投資資本報酬率、資產報酬率方面做得不錯,公司在這兩項指標上已建立良好動能。此外,更重要的是創造長期成長——其所處市場要與Baxter目前競爭的市場相當或更好。所以我會說,敬請期待。如果我們找不到這些收購,無論什麼原因、沒有成案,我們也有資產負債表可用來持續、積極地回購股票。

  • Operator

    Operator

  • And our next question comes from Larry Keusch of Raymond James.

    下一個問題來自Raymond James的Larry Keusch。

  • John Hsu

    John Hsu

  • This is John Hsu on for Larry. Joe, maybe if we could start just following up on your comments on M&A. That was obviously very helpful, but regarding no white spaces, one thing that we saw recently is you, obviously, closed the acquisition of those Mallinckrodt assets, which I believe gives you a new leg in the basic side of the BioSurgery market. So -- and you obviously have leading share on the advanced BioSurgery side. So does your future M&A contemplate opportunities to build out on the basic side? And if so, could you help us kind of size what that opportunity looks like?

    我是代Larry提問的John Hsu。Joe,也許我們先接續你剛才對併購(M&A)的評論。那顯然非常有幫助,但關於不做「白地」收購,我們最近看到的一件事是你們顯然已完成對Mallinckrodt那些資產的收購,我相信這讓你們在BioSurgery市場的基礎端有了新的支點。而你們在進階BioSurgery端顯然擁有領先市占。所以你們未來的併購是否會考慮在基礎端進一步擴建的機會?如果是的話,你能否協助我們大致量化一下那個機會看起來有多大?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • You're talking about building on the advanced surgery side, okay? So we do find ourselves with several opportunities. We still need to create a global portfolio that's more uniform, okay? So we're doing that through organic opportunity. So we'll have an active -- several new products being developed. But we still have need to accelerate the entry in the market in some geographies for some products. So you're going to continue to see an active pursuit from Baxter in part relating to its portfolio across the globe. So we can have similar offerings even if it's regional only, they will fulfill the whole gamut of hemostats and sealants that go, like you said, from your basic hemostat all to more complex variations of FLOSEAL and that allows us to provide the physicians what they need to stop the bleeding and heal the patient.

    你是在談在進階手術端的擴建,對吧?所以我們確實看到自己有幾個機會。我們仍需要打造一個更一致、更均衡的全球產品組合,好嗎?我們正透過有機成長的機會來做這件事。因此我們會有一個活躍的——多項新產品正在開發中。但我們仍需要在某些地理區域、針對某些產品,加速進入市場。所以你會持續看到Baxter積極尋求相關機會,其中一部分與我們在全球的產品組合布局有關。因此我們可以提供類似的產品,即使只是區域性的,也能涵蓋止血劑與封合劑的完整範疇——如你所說,從基礎止血劑一路到更複雜的FLOSEAL變體——讓我們能提供醫師所需的工具來止血並幫助病患癒合。

  • John Hsu

    John Hsu

  • Okay, great. That's really helpful. And then for the follow-up. How do we think about the flu impact in the 1Q or kind of the onetime benefit there?

    好的,很棒。這真的很有幫助。接著追問一下。我們該如何看待第一季(1Q)流感的影響,或其中一次性的利多?

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Yes. The primary area where the flu impacted was our acute business, where we did see outstanding growth. And what I will tell you is the remainder of our business, we did not see a significant change to our core Hospital Products business as a result of the flu, in large part, because of some of the supply constraints that we had in place. But related to the acute business, it was roughly...

    是的。流感影響的主要領域是在我們的急性照護業務,我們確實看到非常亮眼的成長。我想說的是,就我們其餘業務而言,流感並未對我們核心的醫院產品業務造成顯著變化,很大程度上是因為我們當時存在一些供應限制。但就急性照護業務而言,大約是……

  • Clare Trachtman - VP of IR

    Clare Trachtman - VP of IR

  • It was about $8 million of a benefit in the quarter -- $7 million to $8 million of a benefit in the U.S. from the flu in our acute business.

    本季流感在我們急性照護業務上帶來約800萬美元的正面效益——在美國約700萬到800萬美元的受益。

  • Operator

    Operator

  • And our next question comes from Bob Hopkins of Bank of America.

    下一個問題來自美國銀行(Bank of America)的Bob Hopkins。

  • Robert Adam Hopkins - MD of Equity Research

    Robert Adam Hopkins - MD of Equity Research

  • Just have 2 quick questions. First, on the medical delivery side. I'm just curious if you could give us an update on Mexico and bringing incremental supply to the U.S? And is that the reason why things get better in the back half because you just have more capacity?

    我有兩個簡短問題。第一個,關於藥物輸送(medical delivery)業務。我想請問你們能否更新一下墨西哥的情況,以及如何為美國帶來額外供應?而這是否就是為什麼下半年情況會改善——因為你們只是有更多產能?

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Yes. Certainly, we do expect to see incremental volumes in the back part of the year, but there was also a hurricane impact impacting our medication delivery business in the U.S. in the first quarter, north of $10 million. So that was a key driver that we expect to subside in Q2 to Q4.

    是的。我們確實預期在今年後段會看到額外的出貨量,但第一季我們在美國的藥物輸送業務也受到颶風影響,影響金額超過1,000萬美元。因此,我們預期這個關鍵因素會在第二季到第四季逐步消退。

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Yes, Bob, also now thinking about it strategically how we provide product for the U.S. business, the U.S. market needs permanent volume increase from Baxter. So we decided to supplement our volumes of large volume [for inflows], which are the bags that go from 250 mls to 1 liter with 100 million units coming from Mexico on a permanent basis. So what this does for us is threefold. First of all, eases the fear of us ever getting into a situation where the company has been in the last few years, where we had -- struggled with allocations and things of these sorts; second, allows us to go in and pursue new customers; and thirdly, and as important as the other 2 is the fact that we can have time to modernize and remediate our facilities in the U.S. and Puerto Rico. So having this change in how we allocated volumes across the globe is very important. What people sometimes don't remember is Baxter is a global company with the ability to make products in many countries of the world to supply any geography that we need. And, unfortunately, we had different thinking some time ago where we restrict ourselves to geographies. Not anymore. We have the ability to ship products from Brazil into the U.S., from Columbia into the U.S., from Castlebar in Ireland into the U.S. and vice versa. And we also monitor volumes and demand across the globe. So this is a new company that will be there for our patients and customers as they need our solutions.

    是的,Bob,另外從策略面來看,我們如何為美國業務提供產品,美國市場需要Baxter提供永久性的供應量提升。因此我們決定以永久方式,從墨西哥補充我們的大容量輸液袋(large volume [for inflows])供應——也就是從250毫升到1公升的袋裝——每年增加1億單位。這對我們有三個層面的好處。第一,降低我們再次陷入公司過去幾年那種情況的風險——當時我們在配給(allocations)等方面遇到困難;第二,使我們能夠去爭取新客戶;第三,而且同樣重要的是,我們因此能有時間在美國與波多黎各的廠房進行現代化與改善修復。所以,這種在全球範圍內重新分配供應量的改變非常重要。有時大家不記得的是,Baxter是一家全球性公司,能在世界多個國家生產產品,以供應我們需要的任何地理市場。而不幸的是,過去一段時間我們的思維不同,會把自己限制在特定地理區域。現在不會了。我們有能力把產品從巴西運到美國、從哥倫比亞運到美國、從愛爾蘭Castlebar運到美國,反之亦然。我們也會監控全球各地的供應量與需求。因此,這是一家新的公司,會在病患與客戶需要我們解決方案時,隨時提供支援。

  • Robert Adam Hopkins - MD of Equity Research

    Robert Adam Hopkins - MD of Equity Research

  • Very helpful. And then, Joe, just want to ask one sort of big-picture question on the upcoming Analyst Day. Maybe just broadly speaking, how confident are you that there's an organic kind of new product portfolio pipeline at Baxter that can lead to better revenue growth going forward?

    非常有幫助。接著,Joe,我想就即將到來的分析師日問一個比較宏觀的問題。大致來說,你對於Baxter是否有一條有機的新產品組合管線、能在未來帶來更好的營收成長,有多大信心?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Bob, we -- I feel very confident. We are -- if I had to put this in baseball terms, and I hope our audience today understand a little bit of baseball, but I would say that we are at the top of the third inning when it comes to innovation. So we have -- we have set up ourselves well that we have the right research and development team in place right now. We have the right structure in place. And we have really solid strategies by global business unit today. So if I look at the pipeline, every business of ours has a 10-year pipeline. We have technology development teams in place. We have associated ourselves with universities in the case of our sensor for the metric hydration you guys are going to see in May. That has a lot to do with the collaboration between Vanderbilt University and Baxter. So I feel the company has turned the corner in how it learns to innovate. And when I say we're at the top of the third inning because there's a bright future ahead of us. And I think we have now the ability to accelerate, combined with the fact that we're leaning out the organization with an SG&A now sub-22%. So we can now not only deliver the profitability to our investors but also fund some of the innovation that is very needed.

    Bob,我——我非常有信心。我們——如果要用棒球來比喻,而且我希望今天的聽眾多少懂一點棒球,我會說,就創新而言,我們正處於第三局上半。所以我們——我們已經把自己準備得很好,現在有合適的研發團隊到位。我們有正確的架構到位。而且目前各全球事業部都有非常扎實的策略。所以如果我看產品管線,我們每一個事業都有一條10年的產品管線。我們也已建立技術開發團隊。以你們5月會看到的用於衡量水合狀態的感測器為例,我們也與大學合作。那很大一部分來自范德堡大學與Baxter之間的合作。所以我覺得公司在學習如何創新這件事上已經跨過轉折點。我說我們在第三局上半,是因為前方有光明的未來。而且我認為我們現在有能力加速,再加上我們正精簡組織,使SG&A目前降到22%以下。因此我們現在不僅能為投資人交付獲利能力,也能投入資金支持非常需要的創新。

  • Operator

    Operator

  • And our next question comes from Lei Huang of Wells Fargo.

    下一個問題來自富國銀行(Wells Fargo)的Lei Huang。

  • Lei Huang - Associate Analyst

    Lei Huang - Associate Analyst

  • It's Lei calling in for Larry. I just want to start with a question on Suprane. There was a generic FDA approval a couple of months ago, but it doesn't look like it's launched. Can you just talk through how you think about the generic risk? I understand it's not easy to get a generic product in the marketplace. And how you think about the generic risk in your 2018 guidance. And then I have a follow-up.

    我是Lei,代Larry提問。我想先從Suprane的問題開始。幾個月前有一個學名藥獲得FDA核准,但看起來還沒有上市。你能否談談你們如何看待學名藥風險?我理解要把學名藥產品打入市場並不容易。以及你們如何在2018年指引中考量學名藥風險。然後我還有一個追問。

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • We have no impact of this generic Suprane in the marketplace. And the impact that we have in 2018 is not -- there's no -- so our conclusion goes along with what you just said. It's not an easy product to penetrate the marketplace. And we don't think that at the moment in time, there's any threat to our 2018 numbers, neither we have seen anything that concerns us.

    目前這個Suprane學名藥在市場上對我們沒有任何影響。而我們在2018年的影響也不是——沒有——所以我們的結論與你剛才說的一致。這不是一個容易打入市場的產品。而且我們認為就目前而言,對我們2018年的數字沒有任何威脅,我們也沒有看到任何讓我們擔憂的跡象。

  • Lei Huang - Associate Analyst

    Lei Huang - Associate Analyst

  • Great, and then my follow-up is -- so in your Analyst Day, you plan to give an update, I think, on your 2020 outlook and provide longer-term guidance beyond 2020. We have some aspect of your 2020 outlook from prior calls and prior Analyst Day. Would you say you're confident at this point that you would [need] to overachieve your 2020 outlook at this point just based on everything you've done through 1Q '18?

    很好,那我的追問是——在你們的分析師日上,你們計畫更新我想是你們對2020年的展望,並提供2020年之後更長期的指引。我們從先前的電話會議與先前的分析師日已經掌握你們2020年展望的一些內容。你會說你們目前有信心,僅就你們在2018年第一季所做的一切來看,你們將會[需要]超越你們的2020年展望嗎?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • This is like getting a preview of a movie that has now gone to the theaters in the Internet when somebody filmed that illegally in the movie theater. I'm not giving you that one. Wait for it. It's not too far in the future. It's 3.5 weeks. We will be very happy to give you that insight when we are all in New York at the Pierre hotel.

    這就像有人在電影院裡非法偷拍,然後在網路上放出一部已經上映電影的預告片一樣。這題我不回答。等著看吧。不會太久。大概3.5週。等我們大家在紐約皮埃爾飯店(Pierre hotel)見面時,我們會很樂意給你那方面的洞見。

  • Lei Huang - Associate Analyst

    Lei Huang - Associate Analyst

  • Understood. And if I could squeeze one more in, is there any update on the Claris 483?

    了解。如果我可以再塞一個問題,Claris 483有任何最新進展嗎?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • We have complete all the items that we have committed to the FDA. They were going to complete on time. We submitted that to the FDA. We can't speak on behalf of the FDA, but we can speak on behalf of Baxter that we have done everything that we promised to do. And we continue to do because that's not an end game. You just don't do what the FDA asks you to do. We continue to improve, find opportunities to improve our operation at Ahmedabad, and from our estimation, our plant has improved significantly. But we're not the FDA as I said, and I cannot comment on their behalf. But we, at Baxter, continue to be satisfied with the level of improvement that we have seen at our facility.

    我們已完成所有我們承諾要交付給FDA的事項。它們會按時完成。我們已將其提交給FDA。我們無法代表FDA發言,但我們可以代表Baxter發言:我們已經做了所有我們承諾要做的事。而且我們也持續在做,因為那不是終點。你不會只做FDA要求你做的事就結束。我們持續改善,尋找機會改善我們在艾哈邁達巴德(Ahmedabad)的營運;依我們的估計,我們的工廠已顯著改善。但如我所說,我們不是FDA,我不能代他們評論。不過在Baxter,我們對於在我們設施所看到的改善程度,仍然感到滿意。

  • Operator

    Operator

  • And there are no further questions at this time. Ladies and gentlemen, this concludes today's conference call with Baxter International. Thank you for participating, and have a great day.

    目前沒有其他問題。各位女士先生,今天Baxter International的電話會議到此結束。感謝各位參與,祝各位有美好的一天。